Caris Life Sciences (CAI) Retained Earnings (2024 - 2026)

Caris Life Sciences has reported Retained Earnings for 3 years, with the latest figure at $3.1 billion in Q2 2026.

• On a quarterly basis, Retained Earnings rose 0.54% year-over-year to $3.1 billion in Q2 2026; TTM through Jun 2026 was $3.1 billion, a 0.54% increase from a year earlier, with the FY2025 full-year figure at $3.1 billion, up 227.08% from the prior year.
• Retained Earnings was $3.1 billion for Q2 2026 at Caris Life Sciences, down from $3.2 billion in the prior quarter.
• The five-year high for Retained Earnings was $3.2 billion in Q1 2026, with the low at -$2.5 billion in Q4 2024.
• Average Retained Earnings over 3 years is $2.2 billion, with a median of $3.1 billion recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings jumped 227.08% in 2025, then climbed 0.54% in 2026.
• Over 3 years, Retained Earnings stood at -$2.5 billion in 2024, then surged by 227.08% to $3.1 billion in 2025, then retreated by 0.03% to $3.1 billion in 2026.
• The last three Retained Earnings figures came in at $3.1 billion (Q2 2026), $3.2 billion (Q1 2026), and $3.1 billion (Q4 2025), per Business Quant data.